The Pharmacist’s Role in Individualizing Therapy for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, immune-mediated neurologic disorder that can lead to severe disability if left untreated. Early and accurate diagnosis for CIDP is challenging and usually delayed, but early initiation and maintenance of immunoglobulin-based treatment is crucial. Due to the heterogenous nature of the disease, treatment strategies need to be individualized, and pharmacists play an integral role through ongoing patient communications/education, treatment monitoring, dosing adjustments and switching between IVIg to subcutaneous Ig. To support pharmacists in this role, hear faculty offer insights on real-world CIDP cases including challenges with diagnosis and evidence-based treatment strategies for individualizing therapy